|
01 Apr 2019 |
European Medicines Agency Accepts Takeda’s Marketing Authorization Application for a Subcutaneous Formulation of Vedolizumab for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis and Crohn’s Disease
|
|
01 Apr 2019 |
Teva’s AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults
|
|
30 Mar 2019 |
CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis
|
|
30 Mar 2019 |
Northern Biologics Reports Initial Phase I Data for MSC-1 at AACR
|
|
30 Mar 2019 |
Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing
|
|
28 Mar 2019 |
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
|
|
27 Mar 2019 |
Tizona Announces Initiation of Phase 1/1b Study with Novel Cancer Immunotherapy TTX-030 and First Public Presentation of Pre-Clinical Data with TTX-030 at AACR 2019
|
|
27 Mar 2019 |
Eureka Therapeutics Announces Publication of Preclinical Study Demonstrating GPRC5D as a Promising Target for Antibody-Based Therapies in Multiple Myeloma
|
|
26 Mar 2019 |
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
|
|
26 Mar 2019 |
BioInvent and Transgene extend their collaboration to develop multifunctional oncolytic viruses for the treatment of solid tumors
|
|
26 Mar 2019 |
AbbVie Announces First Regulatory Approval of SKYRIZI™ (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan
|
|
22 Mar 2019 |
Genmab Announces European Regulatory Submission for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
|
|
22 Mar 2019 |
Initiation Of Phase III Clinical Trial Of BAN2401 In Early Alzheimer's Disease
|
|
22 Mar 2019 |
GSK announces further positive data from DREAMM-1 study of anti-BCMA antibody-drug conjugate in patients with relapsed/refractory multiple myeloma
|
|
21 Mar 2019 |
Momenta Pharmaceuticals Announces Publication of New Data Supporting M281 as First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in the Human Term Placenta
|
|
21 Mar 2019 |
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease
|
|
21 Mar 2019 |
Innovent Announces First Patient Dosed in a Phase IIa Clinical Study of IBI306, an Anti-PCSK9 Monoclonal Antibody
|
|
21 Mar 2019 |
BioInvent Unveils Broad Anti-TNFR2 Program to Treat Solid Tumors
|
|
21 Mar 2019 |
Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer
|
|
20 Mar 2019 |
I-Mab Biopharma Announces Dosing of First Subject in Phase 1 Clinical Trial of Anti-GM-CSF Monoclonal Antibody TJM2 in the United States
|
|
20 Mar 2019 |
Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
|
|
20 Mar 2019 |
I-Mab Biopharma and MorphoSys Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma
|
|
20 Mar 2019 |
Tiziana Submits IND Application for Oral Formulation of Foralumab for Treatment of NASH
|
|
20 Mar 2019 |
Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases
|
|
19 Mar 2019 |
Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-CD47 Monoclonal Antibody in the U.S.
|
